The FDA says J&J's (JNJ -0.3%) bedaquiline for treating a drug-resistant form of...
The FDA says J&J's (JNJ -0.3%) bedaquiline for treating a drug-resistant form of tuberculosis appears to be "safe and well-tolerated," although the highest dose could cause a small change in the heart's rhythm. J&J is seeking accelerated, temporary approval of bedaquiline; an FDA advisory committee is due to review the drug on Wednesday.
From other sites
at CNBC.com (Fri, 8:17AM)
Video at CNBC.com (Wed, 3:37PM)
Video at CNBC.com (Wed, 1:55PM)
at CNBC.com (Wed, 9:11AM)
Video at CNBC.com (Wed, 8:12AM)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs